Down-modulation of Bcl-2 sensitizes PTEN-mutated prostate cancer cells to starvation and taxanes

Prostate

Volumn 74, Issue 14, 2014, Pages 1411-1422

  Calastretti, Angela ^a   Gatti, Giuliana ^a   Quaresmini, Carolina ^a   Bevilacqua, Annamaria ^a,b  

^a UNIVERSITY OF MILAN   (Italy)

^b SECTION OF MATHEMATICS   (Italy)

Author keywords

Akt; Bcl 2; chemosensitization; nutrient starvation; PTEN; taxanes

Indexed keywords

MESSENGER RNA; PACLITAXEL; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROPIDIUM IODIDE; PROTEIN BCL 2; SMALL INTERFERING RNA; TRYPAN BLUE;

APOPTOSIS; ARTICLE; CELL DEATH; CELL VIABILITY; CELL VIABILITY ASSAY; CHEMOSENSITIZATION; CONTROLLED STUDY; DENSITOMETRY; DOWN REGULATION; HUMAN; HUMAN CELL; LNCAP CELL LINE; MALE; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE CANCER CELL LINE; STARVATION; WESTERN BLOTTING;

AKT; BCL-2; CHEMOSENSITIZATION; NUTRIENT STARVATION; PTEN; TAXANES;

ANTINEOPLASTIC AGENTS, PHYTOGENIC; CELL LINE, TUMOR; DOWN-REGULATION; HUMANS; MALE; MUTATION; PACLITAXEL; PROSTATIC NEOPLASMS; PROTO-ONCOGENE PROTEINS C-BCL-2; PTEN PHOSPHOHYDROLASE;

EID: 84906351267     PISSN: 02704137     EISSN: 10970045     Source Type: Journal    
DOI: 10.1002/pros.22857     Document Type: Article

References (53)

1. Center MM, Jemal A, Lortet-Tieulent J, Ward E, Ferlay J, Brawley O, Bray F,. International variation in prostate cancer incidence and mortality rates. Eur Urol 2012; 61: 1079-1092.
2. Oudard S,. Progress in emerging therapies for advanced prostate cancer. Cancer Treat Rev 2013; 39: 275-289.
3. Smith MR,. Effective treatment for early-stage prostate cancer-possible, necessary, or both ? N Engl J Med 2011; 364: 1770-1772.
4. Kollmeier MA, Zelefsky MJ,. How to select the optimal therapy for early-stage prostate cancer. Crit Rev Oncol Hematol 2012; 83: 225-234.
5. Cannata DH, Kirschenbaum A, Levine AC,. Androgen deprivation therapy as primary treatment for prostate cancer. J Clin Endocrinol Metab 2012; 97: 360-365.
6. Gravis G, Fizazi K, Joly F, Oudard S, Priou F, Esterni B, Latorzeff I, Delva R, Krakowski I, Laguerre B, Rolland F, Théodore C, Deplanque G, Ferrero JM, Pouessel D, Mourey L, Beuzeboc P, Zanetta S, Habibian M, Berdah JF, Dauba J, Baciuchka M, Platini C, Linassier C, Labourey JL, Machiels JP, El Kouri C, Ravaud A, Suc E, Eymard JC, Hasbini A, Bousquet G, Soulie M,. Androgen-deprivation therapy alone or with docetaxel in non-castrate metastatic prostate cancer (GETUG-AFU 15): A randomised, open-label, phase 3 trial. Lancet Oncol 2013; 14: 149-158.
7. Petrylak DP, Tangen CM, Hussain MH, Lara PN Jr, Jones JA, Taplin ME, Burch PA, Berry D, Moinpour C, Kohli M, Benson MC, Small EJ, Raghavan D, Crawford ED,. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 2004; 351: 1513-1520.
8. Tannock IF, de Wit R, Berry WR, Horti J, Pluzanska A, Chi KN, Oudard S, Théodore C, James ND, Turesson I, Rosenthal MA,., Eisenberger MA,. for TAX 327 Investigators. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 2004; 351: 1502-1512.
9. De Bono JS, Oudard S, Ozguroglu M, Hansen S, Machiels JP, Kocak I, Gravis G, Bodrogi I, Mackenzie MJ, Shen L, Roessner M, Gupta S,., Sartor AO, for TROPIC Investigators. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: A randomised open-label trial. Lancet 2010; 376: 1147-1154.
10. Lorente D, De Bono JS,. Molecular alterations and emerging targets in castration resistant prostate cancer. Eur J Cancer 2014; 50: 753-764.
11. Song MS, Salmena L, Pandolfi PP,. The functions and regulation of the PTEN tumour suppressor. Nat Rev Mol Cell Biol 2012; 13: 283-296.
12. Chalhoub N, Baker SJ,. PTEN and the PI3-kinase pathway in cancer. Ann Rev Pathol 2009; 4: 127-150.
13. Liu P, Cheng H, Roberts TM, Zhao JJ,. Targeting the phosphoinositide 3-kinase pathway in cancer. Nat Rev Drug Discov 2009; 8: 627-644.
14. Priulla M, Calastretti A, Bruno P, Azzariti A, Paradiso A, Canti G, Nicolin A,. Preferential chemosensitization of PTEN-mutated prostate cells by silencing the Akt kinase. Prostate 2007; 67: 782-789.
15. Nelson EC, Evans CP, Mack PC, Devere-White RW, Lara PN Jr., Inhibition of Akt pathways in the treatment of prostate cancer. Prostate Cancer Prostatic Dis 2007; 10: 331-339.
16. Pal I, Mandal M,. PI3K and Akt as molecular targets for cancer therapy: Current clinical outcomes. Acta Pharmacologica Sinica 2012; 33: 1441-1458.
17. Thomas C, Lamoureux F, Crafter C, Davies BR, Beralidi E, Fazli L, Kim S, Thaper D, Gleave ME, Zoubeidi A,. Synergistic targeting of PI3K/AKT-pathway and androgen-receptor axis significantly delays castration-resistant prostate cancer progression in vivo. Mol Cancer Ther 2013; 12: 2342-2355.
18. Altman BJ, Rathmell JC,. Metabolic stress in autophagy and cell death pathways. Cold Spring Harb Perspect Biol 2012; 4: a008763.
19. Jin S, DiPaola RS, Mathew R, White E,. Metabolic catastrophe as a means to cancer cell death. J Cell Sci 2007; 120: 379-383.
20. Mason EF, Rathmell JC,. Cell metabolism: An essential link between cell growth and apoptosis. Biochim Biophys Acta 2011; 1813: 645-654.
21. Cory S, Adams JM,. The Bcl2 family: Regulators of the cellular life-or-death switch. Nat Rev Cancer 2002; 2: 647-656.
22. Herbst RS, Khuri FR,. Mode of action of docetaxel-A basis for combination with novel anticancer agents. Cancer Treat Rev 2003; 29: 407-415.
23. Asnaghi L, Calastretti A, Bevilacqua A, D'Agnano I, Gatti G, Canti G, Delia D, Capaccioli S, Nicolin A,. Bcl-2 phosphorylation and apoptosis activated by damaged microtubules require mTOR and are regulated by Akt. Oncogene 2004; 23: 5781-5791.
24. Horoszewicz JS, Leong SS, Kawinski E, Karr JP, Rosenthal H, Chu TM, Mirand EA, Murphy GP,. LNCaP model of human prostatic carcinoma. Cancer Res 1983; 43: 1809-1818.
25. Kaighn ME, Narayan KS, Ohnuki Y, Lechner JF, Jones LW,. Establishment and characterization of a human prostatic carcinoma cell line (PC-3). Invest Urol 1979; 17: 16-23.
26. Stone KR, Mickey DD, Wunderli H, Mickey GH, Paulson DF,. Isolation of a human prostate carcinoma cell line (DU 145). Int J Cancer 1978; 21: 274-281.
27. Sramkoski RM, Pretlow TG 2nd, Giaconia JM, Pretlow TP, Schwartz S, Sy MS, Marengo SR, Rhim JS, Zhang D, Jacobberger JW,. A new human prostate carcinoma cell line, 22Rv1. In Vitro Cell Dev Biol Anim 1999; 35: 403-409.
28. Thompson CB, Bauer DE, Lum JJ, Hatzivassiliou G, Zong WX, Zhao F, Ditsworth D, Buzzai M, Lindsten T,. How do cancer cells acquire the fuel needed to support cell growth ? Cold Spring Harb Symp Quant Biol 2005; 70: 357-362.
29. Lee JT Jr, Steelman LS, McCubrey JA,. Phosphatidylinositol 3'-kinase activation leads to multidrug resistance protein-1 expression and subsequent chemoresistance in advanced prostate cancer cells. Cancer Res 2004; 64: 8397-8404.
30. Fadok VA, Bratton DL, Frasch SC, Warner ML, Henson PM,. The role of phosphatidylserine in recognition of apoptotic cells by phagocytes. Cell Death Differ 1998; 5: 551-562.
31. Persad S, Attwell S, Gray V, Mawji N, Deng JT, Leung D, Yan J, Sanghera J, Walsh MP, Dedhar S,. Regulation of protein kinase B/Akt-serine 473 phosphorylation by integrin-linked kinase: Critical roles for kinase activity and amino acids arginine 211 and serine 343. J Biol Chem 2001; 276: 27462-27469.
32. Calastretti A, Bevilacqua A, Ceriani MC, Viganò S, Zancai P, Capaccioli S, Nicolin A,. Damaged microtubules can inactivate BCL-2 by means of the mTOR kinase. Oncogene 2001; 20: 6172-6180.
33. Vivanco I, Sawyers CL,. The phosphatidylinositol 3-Kinase AKT pathway in human cancer. Nat Rev Cancer 2002; 2: 489-501.
34. Carnero A,. The PKB/AKT pathway in cancer. Curr Pharm Des 2010; 16: 34-44.
35. Jones RG, Thompson CB,. Tumor suppressors and cell metabolism: A recipe for cancer growth. Genes Dev 2009; 23: 537-548.
36. Mosca E, Alfieri R, Maj C, Bevilacqua A, Canti G, Milanesi L,. Computational modeling of the metabolic states regulated by the kinase Akt. Front Physiol 2012; 3: 418.
37. Elstrom RL, Bauer DE, Buzzai M, Karnauskas R, Harris MH, Plas DR, Zhuang H, Cinalli RM, Alavi A, Rudin CM, Thompson CB,. Akt stimulates aerobic glycolysis in cancer cells. Cancer Res 2004; 64: 3892-3899.
38. Song G, Ouyang G, Bao S,. The activation of Akt/PKB signaling pathway and cell survival. J Cell Mol Med 2005; 9: 59-71.
39. Feldman BJ, Feldman D,. The development of androgen-independent prostate cancer. Nat Rev Cancer 2001; 1: 34-45.
40. Sarker D, Reid AH, Yap TA, de Bono JS,. Targeting the PI3K/AKT pathway for the treatment of prostate cancer. Clin Cancer Res 2009; 15: 4799-4805.
41. Schulze A, Harris AL,. How cancer metabolism is tuned for proliferation and vulnerable to disruption. Nature 2012; 491: 364-373.
42. Vander Heiden MG,. Targeting cancer metabolism: A therapeutic window opens. Nat Rev Drug Discov 2011; 10: 671-684.
43. Gleave ME, Miayake H, Goldie J, Nelson C, Tolcher A,. Targeting bcl-2 gene to delay androgen-independent progression and enhance chemosensitivity in prostate cancer using antisense bcl-2 oligodeoxynucleotides. Urology 1999; 54: 36-46.
44. McDonnell TJ, Troncoso P, Brisbay SM, Logothetis C, Chung LW, Hsieh JT, Tu SM, Campbell ML,. Expression of the protooncogene bcl-2 in the prostate and its association with emergence of androgen-independent prostate cancer. Cancer Res 1992; 52: 6940-6944.
45. Raffo AJ, Perlman H, Chen MW, Day ML, Streitman JS, Buttyan R,. Overexpression of bcl-2 protects prostate cancer cells from apoptosis in vitro and confers resistance to androgen depletion in vivo. Cancer Res 1995; 55: 4438-4445.
46. Tang C, Willingham MC, Reed JC, Miyashita T, Ray S, Ponnathpur V, Huang Y, Mahoney ME, Bullock G, Bhalla K,. High levels of p26BCL-2 oncoprotein retard Taxol-induced apoptosis in human pre-B leukemia cells. Leukemia 1994; 8: 1960-1969.
47. Chi KN, Bjartell A, Dearnaley D, Saad F, Schröder FH, Sternberg C, Tombal B, Visakorpi T,. Castration-resistant prostate cancer: From new pathophysiology to new treatment targets. Eur Urol 2009; 56: 594-605.
48. Amaral TM, Macedo D, Fernandes I, Costa L,. Castration-resistant prostate cancer: Mechanisms, targets, and treatment. Prostate Cancer 2012; 2012: 327253.
49. Miayake H, Tolcher A, Gleave ME,. Chemosensitization and delayed androgen-independent recurrence of prostate cancer with the use of antisense Bcl-2 oligodeoxynucleotides. J Natl Cancer Inst 2000; 92: 34-41.
50. Sonpavde G, Matveev V, Burke JM, Caton JR, Fleming MT, Hutson TE, Galsky MD, Berry WR, Karlov P, Holmlund JT, Wood BA, Brookes M, Leopold L,. Randomized phase II trial of docetaxel plus prednisone in combination with placebo or AT-101, an oral small molecule Bcl-2 family antagonist, as first-line therapy for metastatic castration-resistant prostate cancer. Ann Oncol 2012; 23: 1803-1808.
51. Sternberg CN, Dumez H, Van Poppel H, Skoneczna I, Sella A, Daugaard G, Gil T, Graham J, Carpentier P, Calabro F, Collette L,., Lacombe D, EORTC Genitourinary Tract Cancer Group Docetaxel plus oblimersen sodium (Bcl-2 antisense oligonucleotide): An EORTC multicenter, randomized phase II study in patients with castration-resistant prostate cancer. Ann Oncol 2009; 20: 1264-1269.
52. Choo AY, Kim SG, Vander Heiden MG, Mahoney SJ, Vu H, Yoon S-O, Cantley LC, Blenis J,. Glucose addiction of TSC null cells is caused by failed mTORC1-dependent balancing of metabolic demand with supply. Molecular Cell 2010; 38: 487-499.
53. Frezza C, Zheng L, Folger O, Rajagopalan KN, MacKenzie ED, Jerby L, Micaroni M, Chaneton B, Adam J, Hedley A, Kalna G, Tomlinson IP, Pollard PJ, Watson DG, Deberardinis RJ, Shlomi T, Ruppin E, Gottlieb E,. Haem oxygenase is synthetically lethal with the tumour suppressor fumarate hydratase. Nature 2011; 477: 225-228.